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AbstrAct
Large oncosomes (LO) are atypically large (1-10µm diameter) cancer-derived 
extracellular vesicles (EVs), originating from the shedding of membrane blebs and 
associated with advanced disease. We report that 25% of the proteins, identified by 
a quantitative proteomics analysis, are differentially represented in large and nano-
sized EVs from prostate cancer cells. Proteins enriched in large EVs included enzymes 
involved in glucose, glutamine and amino acid metabolism, all metabolic processes 
relevant to cancer. Glutamine metabolism was altered in cancer cells exposed to 
large EVs, an effect that was not observed upon treatment with exosomes. Large EVs 
exhibited discrete buoyant densities in iodixanol (OptiPrepTM) gradients. Fluorescent 
microscopy of large EVs revealed an appearance consistent with LO morphology, 
indicating that these structures can be categorized as LO. Among the proteins 
enriched in LO, cytokeratin 18 (CK18) was one of the most abundant (within the top 
5th percentile) and was used to develop an assay to detect LO in the circulation and 
tissues of mice and patients with prostate cancer. These observations indicate that 
LO represent a discrete EV type that may play a distinct role in tumor progression 
and that may be a source of cancer-specific markers.
IntroductIon
Extracellular vesicles (EVs) that originate from 
cancer cells are gradually and consistently emerging as 
important regulators of tumor progression[1]. Nano-
sized particles called exosomes (~100 nm diameter) are 
generally considered to originate from multivesicular 
bodies (MVB) of the late endocytic pathway[2]. In 
addition to exosomes, tumor cells also produce larger EVs 
(500 to >1000 nm diameter), referred to in general terms as 
microvesicles (MVs)[3-5] or ectosomes. MVs seem to be 
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generated by budding of the plasma membrane. Exosomes 
and other EVs play important functions dictated by their 
cell of origin and their content[6]. After years of research 
aimed to identify unequivocal exosome markers, it is now 
clear that “universal exosome markers” are difficult to 
find, and recent proteomic studies suggest that exosome 
populations are diverse and can be enriched with distinct 
proteins that impart specific functions to the particles[7]. 
Similarly, it is not known whether specific proteins can be 
expressed in exosomes versus plasma membrane-derived 
EVs, such as ectosomes/MVs, and vice-versa.
We recently demonstrated the existence of an 
atypically large class of EVs (1-10 µm in diameter), 
termed large oncosomes (LO), which can be byproducts 
of non-apoptotic plasma membrane blebbing induced by 
silencing of the cytoskeletal regulator Diaphanous-related 
formin-3 (DIAPH3), by overexpression of oncoproteins 
such as MyrAkt1, HB-EGF, and caveolin-1 (Cav-1), 
or by activation of the EGFR[8-11]. In comparison to 
exosomes and MVs, LO are still a poorly characterized EV 
type[12]. Using expression of Cav-1, a circulating marker 
of metastatic prostate cancer[13] to quantify LO, we 
demonstrated a significant increase of LO enumeration in 
the circulation of both TRAMP mice, which harbor rapidly 
progressing prostate tumors, and patients with metastatic 
disease[9]. However, because Cav-1 is also detected in 
exosomes, and our earlier method for LO discrimination 
was simply based on particle size being >1 µm, we went 
on and analyzed the protein content of LO and nano-sized 
EVs using mass spectrometry to identify specific cargo. 
Here we report a quantitative duplex stable isotope 
labeling of amino acids in cell culture (SILAC) analysis 
of large and nano-sized EVs isolated by differential 
centrifugation from DU145 cells silenced for DIAPH3. We 
identified uniquely expressed and differentially expressed 
proteins in the two preparations. Metabolism emerged as 
a biological process enriched in large versus nano-sized 
EVs, and this result was functionally validated. In order to 
validate the mass spectrometry data, to separate EVs from 
particulate material, and to determine the density of large 
EVs, we applied equilibrium centrifugation in OptiPrepTM 
gradients using an upward displacement modality[14-17]. 
Among the proteins enriched in large EVs, cytokeratin 18 
(CK18) emerged as a potential marker for tumor-derived 
EVs in tissues and in plasma. Our findings suggest that 
LO, compared to exosomes, contain different protein 
cargo, are functionally distinct, and harbor proteins that 
might be employed in their functional characterization 
and used as tissue and circulating markers of disease 
progression.
results
silencing of dIAPH3 results in increased shedding 
of large eVs
Consistent with published results, silencing of the 
cytoskeletal regulator DIAPH3 (shDIAPH3) in DU145 
cells resulted in the formation of large plasma membrane 
blebs (1-10 µm in diameter) (Figure 1A, Supplementary 
Movie 1) [8, 10], which were shed into the medium as 
large EVs (Figure 1B). We observed a higher amount of 
total protein in large EVs from shDIAPH3 than control 
cells, collected from the same number of donor cells 
by differential centrifugation (10,000 x g)[3, 10, 18] 
(Supplementary Figure 1A). Flow-cytometry (FACS) 
analysis with specific size beads (1-10 µm), previously 
employed by us to quantify EVs in the size range of 
LO[10], revealed a significantly higher number of EVs > 
1 µm in media from DIAPH3 silenced versus control cells 
(Figure 1C, Supplementary Figure 1B). The result was 
even more robust when we gated for events larger than 2 
µm (Figure 1D), consistent with our previous observation 
that the modal distribution of LO shed from prostate 
cancer cells is 2-3 µm[10]. 
Mass spectrometry identifies differentially 
expressed and unique proteins in large and nano-
sized eVs
Nanoparticle Tracking Analysis (NTA) showed that 
shDIAPH3 DU145 cells also produce higher numbers of 
nano-sized EVs[11]; consequently, we used this system as 
a model to quantitatively compare the protein composition 
of large and nano-sized EVs, isolated by differential 
centrifugation, by SILAC. To minimize false-positive 
hits, two independent SILAC label-swap experiments 
were conducted. Differentially expressed proteins were 
identified by an integrative statistical hypothesis testing 
method with log2-scaled and quantile normalized SILAC 
intensities [19-21]. 
A total of 407 proteins were identified, among which 
103 (approximately 25% of the total) were differentially 
represented in large and nano-sized EVs, with a false 
discovery rate (FDR) < 0.05, and fold change ≥ 2 (Figure 
2A, and Supplementary Figure 2A, B). A volcano plot of 
the differentially expressed proteins showed a noticeable 
enrichment in nano-sized EVs for tetraspanin family 
members CD81 and CD9 (Figure 2A, Supplementary 
Figure 2B), proteins known to be over-represented in 
exosomes[22-24]. Additional top-ranked differentially 
expressed proteins (>4 fold) in nano-sized EVs included 
cell adhesion molecules, such as integrin-α3 (ITGA3), 
integrin-αV (ITGAV), intercellular adhesion molecule 
(ICAM) and CD44. Transforming growth factor-β1 
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(TGFβ1), which has been linked to cancer progression for 
its role in the tumor microenvironment[25, 26], and which 
participates in exosome-mediated biological functions[27, 
28], was 6-fold more abundant in nano-sized versus large 
EVs (Figure 2A). Cathepsin proteases (CTSD and CTSA), 
usually associated with the plasma membrane or secreted 
into the extracellular environment[29], were also enriched 
in nano-sized EVs. 
In contrast, proteins enriched in large EVs included 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 
glucose phosphate isomerase (GPI), lactate dehydrogenase 
B (LDHB), heat shock 70kDa protein 5 (HSPA5), malate 
dehydrogenase (MDH) and aspartate transaminase (GOT) 
family members (Figure 2A, Supplementary Figure 2A). 
These proteins are all involved in metabolic processes 
relevant to cancer[30, 31]. 
We also identified “unique proteins” in both large 
and nano-sized EVs using specific selection criteria (see 
Methods) (Figure 2B). Proteins uniquely identified in 
nano-sized EVs, similarly to the differentially expressed, 
were mainly involved in adhesion, motility, and response 
to hypoxia, functions frequently attributed to exosome 
proteins[32], whereas in large EVs metabolic enzymes 
were also predominant among the unique proteins. 
Notably, glutaminase (GLS), a cytoplasmic enzyme that 
converts glutamine to glutamate, was the most abundant 
protein uniquely identified in large EVs (Figure 2B). 
Further analysis demonstrated that several proteins 
significantly enriched (>4 fold) in large EVs and identified 
in the EV data repository EVpedia[32] were functionally 
categorized as playing a role in cell migration, resistance 
to docetaxel, angiogenesis, prostate cancer progression 
and bone metastasis, and other processes associated with 
tumor progression (Figure 3). These observations indicate 
Figure 1: silencing of dIAPH3 results in increased shedding of large eVs. (A) Membrane blebbing and shedding of EVs of 
variable size (insets) from DU145 cells stably expressing DIAPH3 shRNA, stained with CTxB-FITC (X 63). Scale bar, 20 µm. (B) 30 
min-1h interval frames (from Supplementary Movie 1), acquired by real-time confocal microscopy of DIAPH3-silenced DU145 over-
expressing RFP-tubulin. The arrow points to a membrane bleb that is released as a large oncosome. (C, D) EVs from DIAPH3-silenced or 
parental DU145 cells were analyzed by flow cytometry. 
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that the two EV populations contain different cargo, and 
this might be a reflection of differences in function. 
Functional analysis of the proteins enriched in 
large EVs suggests an influence on cancer cell 
glutamine metabolism
Functional enrichment analysis using FunRich 
software (http://www.funrich.org) further indicated that 
proteins abundant in large EVs are involved in metabolism 
of carbohydrates (15.9%), glucose and glutamine 
metabolism (13.6%), aspartate degradation II (9.1%), and 
gluconeogenesis (13.6%), metabolic processes relevant to 
cancer[33] (Figure 4A). This result provided a rationale 
to determine whether large EVs were capable of inducing 
alterations in glutamine metabolism in recipient cells, a 
role that, to the best of our knowledge, has never been 
tested for any type of EV. Western blotting validated the 
enrichment of metabolic enzymes GOT1 and GAPDH in 
large EVs, whereas the tetraspanin CD63 was enriched 
in nano-sized EVs (Figure 4B). Increased expression of 
GOT1 was also observed in cancer cells exposed to large 
EVs as little as 2 h following exposure, suggesting that the 
protein might be transferred to recipient cells specifically 
via large EVs. GOT1 transcript levels were not altered by 
large EV treatment, thereby supporting protein, and not 
mRNA transfer to recipient cells (Figure 4C). 
Because GOT1 catalyzes the reversible conversion 
from aspartate and α-ketoglutarate to glutamate, we used a 
functional assay that measures the production of glutamate 
per unit time as an indication of GOT activity in cancer 
cells exposed to large and nano-sized EVs[34]. Our results 
indicate a robust stimulation of the enzyme induced by 
large EVs, ultra-purified by buoyant density gradient as 
described in the following paragraph (Figure 4D). We 
also observed a robust increased activity of GOT in cells 
treated with large EVs but not vehicle, and cultured in 
5% but not in 1% glutamine (Supplementary Figure 3A), 
suggesting that EVs stimulate tumor metabolic activities in 
the presence of non-rate limiting amounts of substrate. In 
line with this result, parallel experiments demonstrated an 
increased percentage of S-phase in cells treated with large 
EVs and cultured in 5% but not 1% glutamine (Figure 4E, 
Supplementary Figure 3B). These results indicate that 
large EVs can affect specific metabolic functions of cancer 
cells. 
Large EVs float to 1.10-1.15 g/ml in iodixanol 
centrifugation gradients
From the mass spectrometry analysis we found that 
CK18, a membrane-localized protein we previously used 
Figure 2: Identification of unique and differentially expressed proteins in large and nano-sized EVs. (A) Volcano plots of 
the log2 ratio of the averaged, normalized SILAC intensities against the FDR of the differential expression between large and nano-sized 
EVs. Red and blue dots correspond to proteins enriched in large EVs and nano-sized EVs, respectively. (B) Bar plots show the abundance 
of unique proteins quantified in large (right) and nano-sized EVs (left). The horizontal axis represents the normalized average log2 ion 
intensities of uniquely identified proteins.
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to decorate LO-like features in situ in human prostate 
cancer tissues[10], was highly abundant in large EVs (top 
5th percentile; Figure 5A). In contrast, CD9 and CD81 
were expressed at negligible levels in large EVs (Figure 
5A, inset; Supplementary Figure 2A). To further validate 
the SILAC findings, we performed immunoblotting of 
CK18, which was confirmed to be enriched in large EVs 
(10,000 x g) in comparison with nano-sized EVs (100,000 
x g). In contrast, CD81 was over-represented in nano-sized 
EVs (Figure 5B).
To determine if the proteins identified using 
SILAC were associated with EVs, instead of protein 
clots or debris, and in order to determine the buoyant 
density of large and nano-sized EVs, we used iodixanol 
(OptiPrepTM), a medium that is less viscous than sucrose 
and therefore more likely to enhance the separation of 
EV populations with differing densities[15]. Large and 
nano-sized EV pellets, normalized to the same number of 
cells were separated by flotation in discontinuous 5-60% 
OptiPrepTM density gradients following deposition of the 
EV material at the bottom of the tubes (fractionation by 
upward displacement). Western blot analysis of 10 µg of 
Figure 3: Proteins highly abundant in large eVs are associated with cancer progression. Proteins with >4 fold enrichment 
in large EVs were functionally annotated by using the GO, KEGG and iHOP literature mining softwares to identify the association with 
cancer progression. The column on the right indicates the number of studies, obtained from the EVpedia database, in which these proteins 
were detected. 
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Figure 4: large eVs are enriched in vesicular markers and alter glutamine metabolism in recipient cells. (A) Functional 
analysis using FunRich software indicates the biological pathways overrepresented either in large (10,000 g) or nano-sized EVs (100,000 
g). (B) Protein lysates from cells, large and nano-sized EVs were blotted with the indicated antibodies. CD63 was expressed specifically 
in nano-sized EVs, and GOT1 in large EVs. (C) Protein lysates from DU145 cells untreated or treated with large EVs for the indicated 
times, were blotted with GOT1 antibody. GAPDH was used as a loading control (top panel). GOT1 mRNA expression levels in DU145 
cells untreated or treated with large EVs for the indicated times do not exhibit significant changes. The result is displayed as levels of 
GOT1 transcript after normalization to the housekeeping gene GAPDH in treated versus untreated cells at 2-48h (bottom panel). (D) GOT1 
activity was measured in DU145 cells in 5% glutamine with or without treatment with large oncosomes (1.15 g/ml OptiPrepTM density 
fractions) or exosomes (1.10 g/ml) (20µg/ml of protein lysate). The results from 3 experiments are displayed as relative AST activity in 
treated cells in comparison with the baseline activity of the enzyme (p=0.024). (E) Cell-cycle was analyzed by flow cytometry in DU145 
cells treated with large oncosomes or vehicle in the presence of 1% or 5% glutamine for 24 hours.
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protein lysate obtained from the gradient fractions derived 
from the 100,000 x g pellets revealed a population of 
EVs expressing typical exosome markers, such as CD81 
and tumor susceptibility gene 101 (Tsg101), which were 
detected at a buoyant density of 1.10 g/ml (Figure 5C). 
Transmission electron microscopy (TEM) of this fraction 
revealed a homogeneous population of round, cup-shaped 
vesicles with sizes ranging from 50 to 100 nm, consistent 
with exosome morphology[35] (Figure 5D). Western 
blot analysis of gradient fractions derived from the 
10,000 x g pellets demonstrated that CK18, GAPDH and 
HSPA5, identified as potential large EV markers by mass 
Figure 5: SILAC validation by OptiPreptM gradient, eM and IF. (A) Rank plot of normalized ion intensities of all proteins 
identified in large EVs. CK18 is indicated as high abundant and CD9 and CD81 are indicated as low abundant proteins in large EVs. (B) 
Protein lysates from cells, large EVs and nano-sized EVs were blotted with the indicated antibodies. CD81 was expressed specifically in 
nano-sized EVs, and CK18 in large EVs. (C) Equal amounts of proteins (10 µg) from OptiPrepTM fractions (1-8) of nano-sized EVs were 
blotted with the indicated antibodies. Exosome markers CD81 and Tsg101 were identified in fraction 3, corresponding to the buoyant 
density of 1.10 g/ml. (D) Magnified TEM detail of negative stained EVs corresponding to the buoyant density of 1.10 g/ml, showing cup-
shaped vesicles. Scale bars, 500nm. (E) Equal amounts of proteins (10 µg) from OptiPrepTM fractions (1-8) of large EVs were blotted with 
the indicated antibodies. Large EV enriched proteins (SILAC) such as CK18, GAPDH and HSPA5 were identified in fractions 3 and 4, 
corresponding to the buoyant density of 1.10-1.15 g/ml. (F) The 1.15 g/ml density fraction, labeled with DiO lipophilic dye, was imaged 
by IF. Scale bars, 10 µm and 2 µm (inset).
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spectrometry, floated at buoyant densities of 1.10 and 1.15 
g/ml (Figure 5E). Levels of CD81 and Tsg101 in these 
fractions were negligible or undetectable. Microscopy 
of the 1.15 g/ml fraction, labeled with a fluorescent 
DiO lipophilic dye, revealed the presence of intact EVs, 
variable in size but larger than 1 µm, consistent with LO 
morphology as previously described[8, 10, 18] (Figure 
5F).
cK18 is a marker of large oncosomes and can be 
identified in the circulation and in tissues
Having validated enrichment of CK18 in large EVs 
and specifically in LO by western blotting (Figure 5B, E), 
we attempted to quantify LO shedding from shDIAPH3 
cells by measuring the number of CK18 positive LO by 
FACS, using differentially sized beads (1-10 µm) to set the 
gates[10, 18]. We observed a 17-fold increase of events in 
the PE-positive channel when the EVs were stained with 
CK18 antibody in comparison with unstained vesicles 
(Supplementary Figure 4). 
We then took an analogous approach to 
quantitatively analyze circulating CK18 positive EVs >1 
µm. We used plasma from a previously described mouse 
model in which shDIAPH3 DU145 cells, injected into the 
tail vein, formed a larger number of lung metastatic foci in 
comparison to control cells[10]. We observed a significant 
increase in the mean fluorescent intensity (MFI) of the 
CK18 signal in the plasma EVs of mice injected with 
shDIAPH3 DU145 cells in comparison to mice injected 
with control cells (Figure 6A). Importantly, the tumor 
tissue of the lung metastatic foci of the same animals 
expressed high levels of CK18, and exhibited LO-like 
features, strongly supporting a tumor origin for the large 
EVs detected in the plasma (Figure 6B). 
Finally, as a first test for the potential use of CK18 
as circulating marker in humans, total EVs were isolated 
from human plasma from prostate cancer patients using 
a commercial kit (ExoQuickTM) that does not distinguish 
between LO and exosomes[14, 16]. The rationale for using 
this kit is that it has the potential to be employed clinically 
to isolate EVs and other circulating tumor products. Levels 
of CK18 in ExoQuickTM preparations from prostate cancer 
Figure 6: cK18 is a marker of large oncosomes in vivo. (A) FACS analysis of CK18 positive EVs from the plasma of mice with 
lung metastasis injected with DIAPH3-silenced (n=6) or control (n=4) DU145 cells. The plot shows the mean fluorescent intensity (MFI) 
relative to CK18 positive EVs >1 µm. (B) Representative lung tissue section immunostained with CK18 (4X). The tumor is strongly positive 
for CK18, and LO features can be identified at higher magnification (40X). (c) CK18 western blotting of EVs isolated by ExoQuickTM from 
the plasma of 6 patients with prostate cancer (PCa), and 5 healthy male subjects (Ctrl). Ponceau staining is displayed as a loading control.
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patients (n=6) were significantly higher than in healthy 
control subjects (n=5) (Figure 6C), suggesting that CK18 
in EVs could potentially be used as a circulating cancer 
biomarker. 
dIscussIon
This study reports the first comparative, large 
scale, quantitative analysis of the protein cargo of large 
and nano-sized EVs derived from a metastatic model of 
prostate cancer. We identified unique and differentially 
expressed proteins in the two EV populations. Glutamine 
and glucose metabolism emerged as biological pathways 
enriched in large versus nano-sized EVs. Large EVs with 
the appearance of particles described previously as LO 
could be purified using density gradient centrifugation[14, 
15]. Furthermore, treatment with LO but not with 
exosomes altered aspartate transaminase activity in 
recipient cancer cells. Among the proteins enriched in 
LO, CK18 emerged as a marker for tumor-derived LO in 
tissues and in plasma. 
Cancer cell-derived EVs can be heterogeneous in 
content, size, and density, and have been functionally 
implicated in the regulation of several processes during 
tumor growth and metastasis [5, 6, 36-39]. Despite the 
expectation that EVs derived from plasma membrane 
budding might carry different proteins than EVs derived 
from MVB, recent proteomic studies show a large overlap 
in proteins identified in different types of EVs from the 
same system[17, 40]. Therefore, the substantial overlap 
(69.9%) in proteins identified in this study in large and 
nano-sized EVs is corroborated by previous findings. 
However, the mass spectrometry findings reported here 
were obtained using a quantitative approach, and they 
indicate that levels of proteins identified in both EV types 
are quantitatively distinct. Importantly, although some of 
the proteins we identified in large EVs have been described 
as mitochondrial, the lack of cytochrome P450 argues 
against significant subcellular organelle contamination 
in our preparations [7]. Furthermore, membrane proteins 
constituted 30% of the proteins identified in both EV 
types, consistent with previous reports on EVs[24, 
32]. Our findings that tetraspanins, growth factors (i.e. 
TGFβ1) and proteins related to cell adhesion are enriched 
in nano-sized EVs are consistent with previous reports 
on exosomes [41-43]. Similarly, cathepsin proteases, 
previously reported as EV cargo and involved in ECM 
degradation and remodeling, tumor progression, invasion 
and resistance to chemotherapeutic drugs, was identified 
in nano-sized EVs[29]. Additional studies are necessary 
to determine whether these cathepsin-containing EVs are 
tumor type-specific, and if they could be used as markers 
to purify distinct subtypes of EVs. 
Our study newly demonstrates that we can purify 
large EV populations by floating medium-speed pellets on 
discontinuous density gradients. These particles localize 
to two discrete fractions, floating at 1.10-1.15 g/ml 
density, and shows morphology similar to LO described 
previously[8, 10, 18]. Notably, our density gradient of 
high-speed pellets allowed purification of pure populations 
of exosomes, floating at the original proposed density for 
this well-characterized EV population[14, 17, 44]. Further 
investigation and more granular gradient resolution will 
clarify whether LO have distinct physical properties in 
comparison with exosomes. On a functional point of view, 
while the relevance of exosomes to tumor progression is 
well established, data on LO are still limited. Our findings 
of a stronger association of LO cargo with aggressive 
cancer using GO, KEGG and iHOP literature mining 
softwares, along with the result that metabolism emerges 
as a LO-enriched biological process, suggest a distinct role 
for LO in tumor progression and indicate that these EV 
populations might play a selective metabolic function over 
other EV subclasses. 
Altered glutamine metabolism in tumor cells, 
including a phenotype known as glutamine addiction, 
has been described in aggressive tumors such as glioma, 
melanoma and pancreas carcinoma[34, 45, 46]. We newly 
identified GOT1 as an enriched enzyme in LO and that 
LO can promote glutamine metabolism in recipient cancer 
cells by transferring the protein. However, this may not be 
the only mechanism. In fact, large EVs are also enriched 
in other proteins that affect glutamine metabolism, such 
as HSPA5 (GRP78), which was recently demonstrated to 
promote c-Myc-mediated glutamine flux and proliferation 
of cancer cells[31]. Additionally, HSPA5 expression 
has been correlated with tumor grade and metastatic 
events in triple negative breast carcinoma (TNBC) and 
is functionally relevant to clinical progression[47, 48]. 
Furthermore, GLS, a cytoplasmic enzyme that converts 
glutamine to glutamate is identified in large EVs as a 
unique protein. Alterations in glutamine and glucose 
metabolism are key aspects of the metabolic derangement 
in tumor cells and tumor-associated stroma[49], which 
can promote cancer cell proliferation. Additional 
implications of our findings are that LO may be involved 
in metabolic reprogramming of cells within the tumor 
microenvironment. This hypothesis will be the subject of 
future studies by our laboratory. 
Our identification of CK18 as a protein significantly 
enriched in LO is in line with our previous identification 
of LO-like structures using CK18 IHC in human 
prostate cancer tissues. CK18 was recently detected in 
the circulation of patients with gastric and colorectal 
cancer[50, 51], and linked to a particular subtype of 
prostate cancer that aberrantly expresses p63, lacks the 
androgen receptor (AR) and harbors rearrangements of the 
ERG gene[52]. Expression of CK18 was also reported to 
be maintained in cancer cells after castration, in association 
with loss of AR and appearance of neuroendocrine 
markers, suggesting clinical utility for this luminal type 
cytokeratin[53]. However, this is the first report that 
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identifies CK18 in plasma of patients with prostate cancer. 
This result is promising and suggests the possibility that 
this marker might be adapted for clinical assessment of 
disease status by employing quantitative, high-sensitivity 
detection methods (e.g., ELISA). Taken together, the 
results of this study support further investigation into 
the heterogeneous nature of tumor-derived EVs. They 
also suggest that the characterization of LO, as a distinct 
population from nano-sized exosomes, could result in 
the development of circulating diagnostic or prognostic 
signatures. Ongoing experiments in our laboratory are 
testing the feasibility of employing multiplex labeling of 
LO directly in body fluids. 
MAterIAls And MetHods
cell culture 
DU145 cells, expressing DIAPH3 hRNA or control 
vector, were cultured as previously described[10]. For 
SILAC labeling, DIAPH3-silenced DU145 cells were 
grown for at least six doublings in arginine- and lysine-
depleted DMEM medium supplemented with 10% (v/v) 
dialyzed fetal bovine serum (Invitrogen, Grand Island, 
NY) and L-arginine (Arg0) and L-lysine (Lys0) or 
13C6
15N4-L-arginine (Arg10) and 
13C6
15N2-L-lysine (Lys8) 
(Cambridge Isotope Laboratories, Andover, MA), before 
undergoing isolation of large EVs and nano-sized EVs, 
respectively.
Protein separation and digestion
Proteins were separated and digested as 
described[54]. SILAC-labeled proteins were mixed at a 
1:1 (w/w) ratio, separated by 10% SDS-PAGE, and stained 
with Coomassie Brilliant Blue solution (Bio-Rad). Each 
lane was cut into ten gel slices of similar size and further 
cut into about 1 mm3 particles. Proteins were reduced 
by 10 mM dithiothreitol (DTT), alkylated by 55 mM 
iodoacetamide, and digested with mass spectrometry-
grade trypsin (Promega) at 37°C for 16 h. Tryptic peptides 
were successively extracted with 100 μL of 5% acetic 
acid, 100 μL of 2.5% acetic acid and 50% acetonitrile, 
and 100 μL of 100% acetonitrile. Samples were dried in a 
SpeedVac concentrator (Thermo Scientific) and stored at 
-80°C until MS analysis.
liquid chromatography-tandem mass 
spectrometry
Tryptic peptides were redissolved with 20 μL 
1.5% acetic acid and 5% acetonitrile. Samples (10 μL 
each) were analyzed by online C18 nanoflow reversed-
phase HPLC (Eksigent nanoLC∙2D™) connected to an 
LTQ Orbitrap XL mass spectrometer (Thermo Scientific) 
as described previously[55, 56]. Briefly, samples were 
loaded onto a 15 cm nanospray column (75 μm inner 
diameter, Magic C18 AQ, 3 μm particle size, 200Å pore 
size, Precision Capillary Columns) and separated at 300 
nL/min with a 60-min gradient from 5 to 35% acetonitrile 
in 0.1% formic acid. MS data were acquired in a data-
dependent manner selecting the fragmentation events 
based on the precursor abundance in the survey scan 
(350-1600 Th). The resolution of the survey scan was 
set at 30,000 at m/z 400 Th. Dynamic exclusion was 90 
s. After each survey scan, up to ten collision-induced 
dissociation (CID) MS/MS spectra were acquired in the 
linear ion trap. The mass spectrometry proteomics data 
have been deposited to the ProteomeXchange Consortium 
(http://proteomecentral.proteomexchange.org) via the 
PRIDE partner repository[57] with the dataset identifier 
PXD000776.
Protein identification and quantitation
The MS data were analyzed using MaxQuant 
(v1.3.0.5)[58]. Proteins were identified by searching 
MS/MS spectra against the UniProt database for Human 
(released on 09/11/2012, 84,680 entries) combined with 
262 common contaminants by the Andromeda search 
engine[59], with second peptide identification enabled. 
Carbamidomethylation of cysteines was set as a fixed 
modification, oxidation of methionines and acetylation of 
the protein N-terminus as variable modifications. Trypsin 
allowing for cleavage N-terminal to proline was chosen 
as the enzyme specificity. A maximum of two missed 
cleavages were allowed. The minimum peptide length 
was specified to be seven amino acids. The maximal mass 
tolerance in MS mode was set to 20 ppm for first search 
and 6 ppm for main search, and in MS/MS mode 0.7 Da. 
The maximum false discovery rates (FDR) for peptide and 
protein identifications were specified as 0.01.
Identification of differentially expressed proteins 
(dePs) and functional enrichment analysis
Lists of DEPs (FDR < 0.05 and fold change ≥ 2) 
were identified by integrative hypothesis testing method 
as previously described[21, 60] using quantile normalized 
SILAC intensities[19]. Briefly, for each protein, we 
performed 1) two-tailed t-test and median ratio test; 2) 
computation of false discovery rates (FDRs) from the two 
tests using an empirical distribution of the null hypothesis 
(that the means of the genes are not different), which was 
obtained from random permutations of the samples; 3) 
combination of the two FDRs for the individual peptides 
using Stouffer’s method[20]. In addition, to identify 
proteins uniquely detected in large or nano-sized EVs, we 
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employed the following criteria: 1) being identified in at 
least one replicate with more than two sibling peptides and 
2) being quantified in one single condition, not quantified 
in the other condition. The proteome of large and nano-
sized EVs was analyzed by using functional enrichment 
analysis software FunRich (http://www.funrich.org). 
Isolation of large oncosomes and nano-sized eVs
Large EVs were purified by differential 
centrifugation (Beckman SW28 rotor) from conditioned 
medium or 300 µl of mouse platelet-poor plasma as 
previously described[10, 18]. Briefly, cells and debris 
were eliminated by centrifugation at 2,800 g for 10 min. 
The supernatant was then centrifuged at 10,000 g for 30 
min to precipitate large EVs. For isolation of nano-sized 
EVs, the supernatant remaining after the 10,000 g spin was 
subjected to additional centrifugation at 100,000 g for 60 
min. For discontinuous centrifugation gradient we used 
a modified version of a previously applied protocol[61]. 
Briefly 60%, 50%, 40%, 30%, 25%, 15%, 10% and 
5% solutions were made by diluting a stock solution of 
OptiPrep™ (60% aqueous iodixanol from Sigma) in 0.25 
M Sucrose/0.9 M NaCl/ 120 mM HEPES, pH 7.4. The 
10,000 x g and 100,000 x g pellets were mixed in the 
bottom layer and the following solutions carefully layered. 
Centrifugation was performed at 100,000 x g for 3h and 50 
min at 4 °C with a SW28 Beckman rotor. Eight individual 
fractions were collected, washed with PBS, and after 
centrifugation at 100,000 x g for 1 h at 4 °C, the pellet 
from each fraction suspended in either PBS or lysis buffer. 
FAcs analysis of large eVs
Purified large EVs from conditioned media or mouse 
plasma samples (6 shDIAPH3 and 4 control) were washed 
in PBS, fixed and permeabilized with 0.5% Tween 20 and 
then stained with rabbit monoclonal CK18 (Abcam, 1:50). 
Samples were processed on a LSRII Flow Cytometer (BD) 
using 1, 2 and 10 µm bead standards[10, 18]. A minimum 
of 3000 events per experiment was recorded and the 
data analysis was performed with the FlowJo software 
(Treestar). The plot shows the mean fluorescent intensity 
(MFI). Statistical significance was calculated using a 
2-tailed unpaired Student’s t test.
Isolation of eVs from human plasma
EVs were isolated from human plasma (in 
accordance with Ethics Board Approval Cert. H09-
01010 obtained from the University of British Columbia, 
Canada) using precipitation solution ExoQuick™ (System 
biosciences) according to the manufacturer’s manual with 
a few modifications. Briefly, 500 µl of plasma samples 
from prostate cancer patients and disease-free normal 
controls were diluted with 1X PBS (1:1). ExoQuick™ 
solution was added to the plasma, gently mixed and stored 
at 4º C overnight. The plasma samples were centrifuged at 
1,500 x g for 30 min and the resulting exosome pellet was 
suspended in PBS. EVs pellet was stored at -80ºC until 
further analysis. 
Fluorescence microscopy
Cells were stained with FITC-conjugated cholera 
toxin B (CTxB) subunit (Sigma) and imaged using an 
Axioplan 2 microscope (Zeiss), as previously described[8, 
10, 18]. Alternatively, control or DIAPH3-silenced cells 
were imaged by a 20x objective on an Ultravox Spinning 
Disc Confocal microscope at the Boston Children’s 
Hospital Intellectual and Developmental Disabilities 
Research Imaging Core facility (IDDRC, NIH-P30-
HD-18655). The 25% iodixanol fraction, corresponding 
to the 1.15 g/ml fraction were stained with the lipophilic 
tracer DiO (Invitrogen) and imaged using a Leica TCS SP 
spectral confocal microscope. 
transmission electron microscopy
EVs from the 15% iodixanol fraction 100,000 x 
g, corresponding to the 1.10 g/ml fraction were washed 
in HEPES, fixed with 1% glutaraldehyde and layered 
onto a mesh copper grids. Grids were then stained with 
the Negative Staining (NS) technique. Imaging was 
performed at an acceleration voltage by a transmission 
electron microscope JEM1200EX (JEOL, Japan) provided 
with a BioScan 600W digital camera (Gatan, USA).
Immunoblot analysis
Cells, purified large EVs and nano-sized EVs were 
lysed and analyzed by western blotting using the following 
antibodies: rabbit monoclonal GOT1 (Sigma, 1:1000 
dilution), rabbit polyclonal CD63, clone H-193 (Santa 
Cruz, 1:1000 dilution), rabbit polyclonal CK18 (Abcam, 
1:1000 dilution); rabbit polyclonal CD81, clone M38 
(Abcam, 1:1000 dilution), mouse monoclonal TSG101, 
clone C-2 (Santa Cruz, 1:500 dilution), rabbit monoclonal 
HSPA5 (Cell Signaling, 1:1000), and GAPDH (Cell 
Signaling 1:2000). 
Immunoblot and qrt-Pcr analysis for Got1 in 
cells exposed to eVs
DU145 cells, exposed to vehicle or large EVs for 
the indicated times, were blotted with GOT1 and GAPDH 
antibodies. mRNA from DU145 cells, exposed to vehicle 
or large EVs for the indicated times, was analyzed by 
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qRT-PCR with commercially available specific primers 
for GOT1 and GAPDH (Hs.PT.58.45409452, and 
Hs.PT.39a22214836, respectively) (Integrated DNA 
Technologies).
Aspartate Aminotransferase Activity Assay
Parental DU145 cells were treated with either 
1.15 g/mL (large EVs) or 1.10 g/mL (exosomes) density 
fractions (20µg/ml of protein lysate) for 24 h in presence 
of 1% or 5% glutamine and then analyzed by using an 
Aspartate Aminotransferase Activity Assay kit following 
the manufacturer’s instructions (Sigma). Statistical 
significance was calculated using a 2-tailed unpaired 
Student’s t test among the relative biological replicates.
Cell cycle analysis of DU145 cells exposed to large 
oncosomes
1x105 DU145 cells were plated in 6 well plates 
overnight and then treated with large EVs or vehicle for 
24 h, in presence of 1% or 5% glutamine. Cells were 
fixed, permeabilized, treated with RNAses (50µg/ml), 
and labeled with Propidium Iodide (5µg/ml). At least 
10,000 events per experiment were recorded using a 
LSRII cytometer (BD Biosciences) and a BD FACSDiva 
software. Data analysis was performed with the FlowJo 
software (Treestar). 
lung mouse tissue staining
Lung mouse tissues from animals injected 
with shDIAPH3 DU145 cells into the tail vein were 
immunostained with CK18[9] and imaged by light 
microscopy. 
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